IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII

The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore, any control of their FVIII-reactive lymphocy...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Invest
Main Authors: Matino, Davide, Gargaro, Marco, Santagostino, Elena, Di Minno, Matteo N.D., Castaman, Giancarlo, Morfini, Massimo, Rocino, Angiola, Mancuso, Maria E., Di Minno, Giovanni, Coppola, Antonio, Talesa, Vincenzo N., Volpi, Claudia, Vacca, Carmine, Orabona, Ciriana, Iannitti, Rossana, Mazzucconi, Maria G., Santoro, Cristina, Tosti, Antonella, Chiappalupi, Sara, Sorci, Guglielmo, Tagariello, Giuseppe, Belvini, Donata, Radossi, Paolo, Landolfi, Raffaele, Fuchs, Dietmar, Boon, Louis, Pirro, Matteo, Marchesini, Emanuela, Grohmann, Ursula, Puccetti, Paolo, Iorio, Alfonso, Fallarino, Francesca
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Clinical Investigation 2015
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4607121/
https://ncbi.nlm.nih.gov/pubmed/26426076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI81859
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker